Publications by authors named "Andrew See"

Claim this Profile
F
Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial.
Andrew W See, Paul Conway, Mark Frydenberg, Hodo Haxhimolla, Anthony J Costello

Int J Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial.
Andrew W See, Patrick Bowden, Geoffrey Wells, Sree Appu, Nathan Lawrentschuk

Radiat Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial.
Patrick Bowden, Andrew W See, Kevin So, Nathan Lawrentschuk, Daniel Moon

World J Urol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution.
Elliot Anderson, Lloyd M L Smyth, Richard O'Sullivan, Andrew Ryan, Nathan Lawrentschuk, Andrew W See

Transl Androl Urol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.
Angelyn Anton, Olfat Kamel Hasan, Zita Ballok, Patrick Bowden, Anthony J Costello, Andrew See

BJU Int· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial.
Patrick Bowden, Andrew W See, Mark Frydenberg, Hodo Haxhimolla, Anthony J Costello

Int J Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study.
Chloe Pandeli, Lloyd M L Smyth, Steven David, Andrew W See

Radiat Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic radiosurgery for brain and spine metastases.
Patrick J Bowden, Andrew W See, Michael J Dally, Richard G Bittar

J Clin Neurosci· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Maroie Barkati, Scott G Williams, Farshad Foroudi, Keen Hun Tai, Sarat Chander, Andrew See

Int J Radiat Oncol Biol Phys· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer.
Daisy Mak, Daryl Lim Joon, Michael Chao, Morikatsu Wada, Michael Lim Joon, Andrew See

Radiother Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the impact of FDG-PET in the management of anal cancer.
Brandon T Nguyen, Daryl Lim Joon, Vincent Khoo, George Quong, Michael Chao, Andrew See

Radiother Oncol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the effect of marked normal structure volume on normal tissue complication probability.
Colin J Hornby, Trevor Ackerly, Andrew See, Moshi Geso

Med Dosim· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose distribution and morbidity after high dose rate brachytherapy for prostate cancer: influence of V150 and V200 parameters.
Gillian M Duchesne, Ram Das, Warren Toye, Andrew See

Australas Radiol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis